The future of targeted cell therapy against cancer
NKILT Therapeutics is redefining the future of cancer treatment with allogeneic and off-the-shelf cell therapy.
A cutting-edge cell therapy biotech in seed stage
NKILT Therapeutics is developing a novel allogeneic, off-the-shelf approach to engineering immune cells, starting with natural killer (NK) cells, to directly target leukemias and solid tumors.
A platform with exceptional potential
Our platform focuses initially on allogeneic NK cells through a completely unique and novel approach of natural receptor binding called Chimeric ILT-Receptor (CIR).
Has potential in >50% of cancers
Our target, HLA-G, has broad expression across tumor types.
Our CIR technology combines exquisite natural specificity with unique signaling.
Optimizes signal transduction
Our NK cells have longer activation in vivo.
Exploits tumor vulnerability
HLA-G is found in both the tumor and the inhibitory tumor microenvironment (TME).
We anticipate further developing our CIR technology through other immune cells, such as T cells and invariant natural killer T (iNKT) cells.
Our engineered NK cells will not only directly kill cancer cells but also activate innate and adaptive immunity and directly target tumor defense mechanisms.
The latest from NKILT
See where our team is presenting the latest data and updates on our CIR technology.
Innate Killer Summit
- Hilton La Jolla Torrey Pines
La Jolla, San Diego, CA, USA
- March 28-30, 2023
ARM Cell & Gene Meeting on the Med
- Hotel Arts Barcelona
- April 12-14, 2023